Clinical Impact of Vitamin D Treatment in Cystic Fibrosis: a Pilot Randomized, Controlled Trial

Overview

Journal Eur J Clin Nutr

Specialty Nutritional Sciences

Date 2016 Dec 15

PMID 27966575

Citations 19

Authors

T Pincikova

D Paquin-Proulx

J K Sandberg

M Flodstrom-Tullberg

L Hjelte

Affiliations

Soon will be listed here.

Abstract

Background/objectives: Vitamin D insufficiency in cystic fibrosis is common. Vitamin D3 is currently preferred over D2. We aimed to study the efficacy of vitamin D2 and D3 at increasing serum 25-hydroxyvitamin D (s25OHD) concentrations and their effect on respiratory health in cystic fibrosis.

Subjects/methods: Sixteen CF patients were randomized to receive vitamin D2 or D3 or to serve as controls. The starting dose of 5000 IU (<16 years old) or 7143 IU/day (⩾16 years old) was further individually adjusted. Three months of intervention were followed by two of washout (ClinicalTrials.gov NCT01321905).

Results: To increase s25OHD, the mean daily dose of vitamin D2 and D3 had to be increased up to 15650 and 8184 IU, respectively. The combined group of vitamin D2 and D3 treated patients decreased plasma IL-8 (P<0.05). Patients provided vitamin D3 improved FVC at the end of the trial (P<0.05). Change in s25OHD was positively correlated with changes in the adult Quality-of-Life respiratory score at the end of supplementation (P=0.006, r=0.90), and with changes in FEV1 (P=0.042, r=0.62) and FVC (P=0.036, r=0.63) at one month of washout.

Conclusions: Vitamin D supplementation may contribute to reduced inflammation and improved lung function in CF.

Citing Articles

Vitamin D deficiency in patients with cystic fibrosis: a systematic review and meta-analysis.

Farahbakhsh N, Fatahi S, Shirvani A, Motaharifard M, Mohkam M, Tabatabaii S J Health Popul Nutr. 2024; 43(1):11.

PMID: 38233891 PMC: 10795301. DOI: 10.1186/s41043-024-00499-2.

Hope in Every Breath: Navigating the Therapeutic Landscape of Cystic Fibrosis.

Sreenivasulu H, Muppalla S, Vuppalapati S, Shokrolahi M, Reddy Pulliahgaru A Cureus. 2023; 15(8):e43603.

PMID: 37719614 PMC: 10504422. DOI: 10.7759/cureus.43603.

Changes in bone turnover after high-dose vitamin D supplementation during acute pulmonary exacerbation in cystic fibrosis.

Wu M, Bhimavarapu A, Alvarez J, Hunt W, Tangpricha V Bone. 2023; 174:116835.

PMID: 37390941 PMC: 10428002. DOI: 10.1016/j.bone.2023.116835.

Nutritional Care in Children with Cystic Fibrosis.

Mariotti Zani E, Grandinetti R, Cunico D, Torelli L, Fainardi V, Pisi G Nutrients. 2023; 15(3).

PMID: 36771186 PMC: 9921127. DOI: 10.3390/nu15030479.

A Single Vitamin D Bolus Supplementation Improves Vitamin D Status and Reduces Proinflammatory Cytokines in Healthy Females.

Alsufiani H, Alghamdi S, Alshaibi H, Khoja S, Saif S, Carlberg C Nutrients. 2022; 14(19).

PMID: 36235615 PMC: 9570631. DOI: 10.3390/nu14193963.

References

Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson K . An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012; 97(4):1082-93. DOI: 10.1210/jc.2011-3050. View

Sexauer W, Hadeh A, Ohman-Strickland P, Zanni R, Varlotta L, Holsclaw D . Vitamin D deficiency is associated with pulmonary dysfunction in cystic fibrosis. J Cyst Fibros. 2015; 14(4):497-506. DOI: 10.1016/j.jcf.2014.12.006. View

Vanstone M, Egan M, Zhang J, Carpenter T . Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2015; 50(5):441-6. DOI: 10.1002/ppul.23161. View

Sermet-Gaudelus I, Bianchi M, Garabedian M, Aris R, Morton A, Hardin D . European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros. 2011; 10 Suppl 2:S16-23. DOI: 10.1016/S1569-1993(11)60004-0. View

Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L . Vitamin D3: a helpful immuno-modulator. Immunology. 2011; 134(2):123-39. PMC: 3194221. DOI: 10.1111/j.1365-2567.2011.03482.x. View